IntelliGender release raises abortion fears
By Courier Mail,
Courier Mail
| 05. 10. 2009
A test that claims to determine the sex of an unborn baby only eight weeks into a pregnancy will be available in pharmacies from today.
IntelliGender, the first test of its kind in Australia, claims a 90 per cent accuracy rate in determining whether a baby will be a boy or a girl.
Doctors and the anti-abortion lobby, however, fear the test will be used as a means of sex selection and drive up abortion rates.
The company behind the $95 test, which has been sold in the US since 2006, says it takes 10 minutes and identifies a "confidential element" found in the hormones of a woman pregnant with a girl.
The element is found in very low levels in women pregnant with a boy or not pregnant at all.
Currently, women who want to find out their baby's gender can do so at a routine 18- to 20-week ultrasound to check on the health and development of the child.
Royal Australian and New Zealand College of Obstetricians and Gynaecologists president Dr Ted Weaver said there appeared to be...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...